The authors used a specialized PROTAC molecule, which induced the BCL-XL degradation, leading to Treg apoptosis within the tumor microenvironment, suggesting a novel strategy to boost anti-tumor immune responses (156). This evidence concerns the gene BCL2L1 and neoplasm.